Scientific Reports
February 11, 2023
Grant Jones, Joshua Lipson, Erica Wang
2 citations
Abstract Impairment in social functioning is a common source of morbidity across many mental health disorders, yet there is a dearth of effective and easily implemented interventions to support social functioning. MDMA/ecstasy and classic psychedelics (psilocybin, LSD, peyote, mescaline) represent two potential treatments for impairments in social functioning, as evidence suggests these...
Frontiers in Psychiatry
February 9, 2023
Kees Kramers, Arnt Schellekens, Metten Somers et al.
119 citations
Background Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted...
Toxics
February 3, 2023
Luis Alberto Henríquez-Hernández, Jaime Rojas-Hernández, Domingo Jesús Quintana Hernández et al.
21 citations
Psychedelics are experiencing a strong renaissance and will soon be incorporated into clinical practice. However, there is uncertainty about how much harm they can cause at what doses. This review aimed to collect information on the health-hazardous doses of psychedelic substances, to be aware of the risks to which patients may be subjected. We focused on ergolamines, simple tryptamines, and...
Behavioral Neuroscience
February 1, 2023
S. Marc Breedlove, Neil V. Watson
This chapter explores the birth of a pharmaceutical problem, using the discovery of lysergic acid diethylamide (LSD) by Albert Hofmann as an example. Hofmann, working for Sandoz Pharmaceuticals, was researching compounds derived from ergot when he accidentally ingested a small amount of an experimental compound and experienced intense visual phenomena. This led to the realization that the...
Communications Biology
January 28, 2023
Andrea I. Luppi, Jakub Vohryzek, Morten L. Kringelbach et al.
98 citations
A central question in neuroscience is how consciousness arises from the dynamic interplay of brain structure and function. Here we decompose functional MRI signals from pathological and pharmacologically-induced perturbations of consciousness into distributed patterns of structure-function dependence across scales: the harmonic modes of the human structural connectome. We show that...
January 16, 2023
Daisy Lutyens
1 citation
<p>Examining participants’ experiences self-medicating with LSD, psilocybin, and MDMA, this exploratory study sought to determine whether psychedelics have a future in New Zealand mental health treatment. This thesis employed a mixed-methods approach to data collection, by collecting broad-brush quantitative data via a Qualtrics survey, which then informed the qualitative data collection method...
Journal of Psychedelic Studies
January 16, 2023
Benjamin A. Korman
7 citations
Abstract Background and aims Although large-scale population studies have linked the use of classic psychedelics (lysergic acid diethylamide, psilocybin, or mescaline) to reduced odds of physical health problems, mental health problems, and criminal behavior, the roughly 35 million adults in the United States who have used classic psychedelics are nonetheless stigmatized in the American job...
Frontiers in Psychiatry
January 10, 2023
Jonina Rabinowitz, Raz Gross, Shaul Lev-Ran
15 citations
Objective Classic psychedelics (LSD, psilocybin, and peyote/mescaline) have been used to support addiction treatment in a variety of contexts ranging from ceremonial use to clinical trials. The aim of this study was to test the hypothesis that past naturalistic use of classic psychedelics would be associated with decreased prevalence of substance use disorder, when controlling for known...
Frontiers in Psychiatry
January 4, 2023
Felix P. Mayer, Dino Luethi, Lorena B. Areal et al.
1 citation
The consumption of psychoactive substances is inextricably linked with human history. Longstanding evidence supports the consumption of psychoactive substances that are found in plants and fungi (e.g. cathinone and muscimol, which are present in Catha edulis and Amanita muscaria, respectively) and alcoholic beverages. With the advent of more refined chemical approaches, isolated (e.g. cocaine)...
Pain Practice
January 4, 2023
Tim Willegers, Anke Reuser, Cornelis Kramers et al.
38 citations
Abstract Aims We aim to provide an evidence‐based overview of the use of psychedelics in chronic pain, specifically LSD and psilocybin. Content Chronic pain is a common and complex problem, with an unknown etiology. Psychedelics like lysergic acid diethylamide (LSD) and psilocybin, may play a role in the management of chronic pain. Through activation of the serotonin‐2A (5‐HT2A) receptor,...